# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

-	the Registrant ⊠ a Party other than the Registrant □
Check th	ne appropriate box:
	Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Definitive Proxy Statement  Definitive Additional Materials  Soliciting Material Pursuant to § 240.14a-12
	Talis Biomedical Corporation
	(Name of Registrant as Specified In Its Charter)
	(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment	of Filing Fee (Check all boxes that apply):
	No fee required.  Fee paid previously with preliminary materials  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



### TALIS BIOMEDICAL CORPORATION

2022 Annual Meeting Vote by June 9, 2022 11:59 p.m. ET



\* TALIS

D81565-P72820

#### You invested in TALIS BIOMEDICAL CORPORATION, and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 10, 2022.

Get informed before you vote

View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 27, 2022. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #



Point your camera here and vote without entering a control number





Vote Virtually at the Meeting\*

June 10, 2022 7:30 a.m., Pacific Time

www.virtualshareholdermeeting.com/TLIS2022

<sup>\*</sup>Please check the meeting materials for any special requirements for meeting attendance.

## THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Vo	ting Items	Recommends
1.	Election of Directors	
	Nominees:	350
1a.	Felix Baker, Ph.D.	For
1b	Melissa Gilliam, M.D., M.P.H.	For
1c.	Matthew L. Posard	For
2.	Approval of an Amendment to the Talis Biomedical Corporation 2021 Equity Incentive Plan.	For
3.	Approval of an Amendment to the Talis Biomedical Corporation 2021 Employee Stock Purchase Plan.	For
4.	Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.	For
NC the	OTE: In their discretion, the proxyholders are authorized to vote upon such other business as may properly come before meeting or any adjournment or postponement thereof.	
	Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-del	ivery".

D81566-P72820